Jim Davis

You mentioned the Haystack minimally residual disease testing that looks for very, very small remnants of the cancer that may remain either post-surgery or post-chemotherapy.

So it's a growing portion of our portfolio of testing today.

Now, in addition, we offer a lot of routine cancer tests, PSA screening, all sorts of different types of cancer markers at the screening phase.

So all told, cancer of our $11 billion portfolio today, cancer in its entirety is about a billion dollars of our portfolio.